drugset / Trial / NCT01111591
Cyclooxygenase-2 Inhibitor for Adjuvant Anticancer Effect in Patients With Biliary-pancreas Cancer
Phase 4
Unknown
220 enrolled
Seoul National University Hospital
Seoul National University Bundang Hospital · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
In extrahepatic bile duct cancer and pancreatic cancer, we will treat postoperatively with COX2 inhibitor and assess survival rate and recurrent rate.
Timeline
- Start
- 2008-11
- Primary completion
- 2017-06
- Completion
- 2017-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Celecoxib | Other / unclassified | 200 mg | — |